John Prendergast, Lead Independent Director at North Carolina-based Nasdaq-listed Heat Biologics, talks through the company’s Phase II clinical trial for non-small cell lung cancer, in combination with Bristol-Myers Squibb’s nivolumab (Opdivo^®).

This interview took place on 14 November 2017 at Biotech and Money’s Inv€$tival Showcase in London. The video was filmed and produced by the well-known retail website London South East.